Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498914 · ClinicalTrials.gov registry record · Phase 2
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00498914 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 41 participants.
The verdict
NCT00498914, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155
Interventions
- DRUG YM155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498914
The ClinicalTrials.gov registry entry for NCT00498914 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which YM155 is the first listed.
NCT00498914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498914 about?
NCT00498914 is a clinical study titled "Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects". A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155
What is the current status of trial NCT00498914?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00498914?
The interventions under investigation include: YM155 (DRUG).
Who is sponsoring clinical trial NCT00498914?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.